Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bristol-Myers Squibb is set to acquire US-based Amira Pharmaceuticals under a definitive agreement signed between the companies for a price of $325m upfront and additional payments totaling $150m.
Subscribe to our email newsletter
As per the terms of the agreement, Bristol-Myers Squibb will take over all of Amira’s issued and outstanding shares of capital stock and stock equivalents.
Bristol-Myers Squibb will also secure Amira’s fibrosis programme, including lead asset AM152, and the preclinical autotaxin programme.
Bristol-Myers Squibb Research and Development executive vice president, chief scientific officer and president Elliott Sigal said the acquisition represents a targeted set of transactions designed to enrich the company’s pipeline with potential medicines to help patients in need.
The closing of the transaction is subject to customary regulatory approvals.